TTM
$50.93B
YoY change
+16.0%
5Y CAGR
+18.8%
Peak year (2025)
$48.18B
Cumulative revenue
$404.37B
Revenue history chart for Novo Nordisk (NVO) from 1985 to 2025
Latest: $48.18B
Revenue growth chart for Novo Nordisk (NVO) from 1985 to 2025
Latest: +16.0%
Revenue history table for Novo Nordisk (NVO) from 1985 to 2025
| 2025 | $48.18B | +16.0% | +$6.65B | ||
| 2024 | $41.53B | +23.9% | +$8.00B | ||
| 2023 | $33.52B | +37.9% | +$9.21B | ||
| 2022 | $24.31B | +12.3% | +$2.67B | ||
| 2021 | $21.65B | +6.4% | +$1.30B | ||
| 2020 | $20.35B | +12.5% | +$2.26B | ||
| 2019 | $18.08B | +5.8% | +$987.22M | ||
| 2018 | $17.10B | -3.3% | −$577.78M | ||
| 2017 | $17.67B | +9.1% | +$1.48B | ||
| 2016 | $16.20B | +2.2% | +$353.71M | ||
| 2015 | $15.84B | +6.3% | +$942.01M | ||
| 2014 | $14.90B | -2.3% | −$353.57M | ||
| 2013 | $15.25B | +12.4% | +$1.68B | ||
| 2012 | $13.57B | +13.0% | +$1.56B | ||
| 2011 | $12.02B | +8.5% | +$944.44M | ||
| 2010 | $11.07B | +9.2% | +$936.43M | ||
| 2009 | $10.13B | +25.3% | +$2.04B | ||
| 2008 | $8.09B | -0.6% | −$46.59M | ||
| 2007 | $8.14B | +21.4% | +$1.43B | ||
| 2006 | $6.71B | +24.7% | +$1.33B | ||
| 2005 | $5.38B | +5.2% | +$267.76M | ||
| 2004 | $5.11B | +16.0% | +$704.34M | ||
| 2003 | $4.40B | — | — | ||
| 2002 | — | — | — | ||
| 2001 | — | — | — | ||
| 2000 | — | — | — | ||
| 1999 | — | — | — | ||
| 1998 | — | — | — | ||
| 1997 | — | — | — | ||
| 1996 | — | — | — | ||
| 1995 | — | — | — | ||
| 1994 | — | — | — | ||
| 1993 | — | — | — | ||
| 1992 | — | — | — | ||
| 1991 | — | — | — | ||
| 1990 | — | — | — | ||
| 1989 | — | — | — | ||
| 1988 | — | — | — | ||
| 1987 | — | — | — | ||
| 1986 | — | — | — | ||
| 1985 | — | — | — |
- 2025$48.18B+16.0%
- 2024$41.53B+23.9%
- 2023$33.52B+37.9%
- 2022$24.31B+12.3%
- 2021$21.65B+6.4%
- 2020$20.35B+12.5%
- 2019$18.08B+5.8%
- 2018$17.10B-3.3%
- 2017$17.67B+9.1%
- 2016$16.20B+2.2%
- 2015$15.84B+6.3%
- 2014$14.90B-2.3%
- 2013$15.25B+12.4%
- 2012$13.57B+13.0%
- 2011$12.02B+8.5%
- 2010$11.07B+9.2%
- 2009$10.13B+25.3%
- 2008$8.09B-0.6%
- 2007$8.14B+21.4%
- 2006$6.71B+24.7%
- 2005$5.38B+5.2%
- 2004$5.11B+16.0%
- 2003$4.40B—
- 2002——
- 2001——
- 2000——
- 1999——
- 1998——
- 1997——
- 1996——
- 1995——
- 1994——
- 1993——
- 1992——
- 1991——
- 1990——
- 1989——
- 1988——
- 1987——
- 1986——
- 1985——
Revenue values are taken from Novo Nordisk's reported income statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts converted to USD using IAS 21 average exchange rates (P&L / cash flow) or closing rates (balance sheet). Originally filed in DKK.
About Revenue at Novo Nordisk (NVO)
According to Novo Nordisk's latest reported financial statements, the company's current revenue (TTM) is $50.93B. Revenue is the total income from selling goods or services before any expenses. Unlike net income (earnings), revenue does not subtract operating costs, taxes, or other charges. Figures are in USD; chart and tables below use historical filings.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual revenue for Novo Nordisk (NVO) came in at 309.06B DKK – grew 6.4% year-over-year.
Novo Nordisk revenue compound annual growth for the 2020–2025 (5 years) window is +19.5%, sustaining 8 straight years of year-over-year growth.
The highest annual revenue of 309.06B DKK was reported in 2025. The lowest in the available history was 4.16B DKK in 1985.
Novo Nordisk Revenue by Year
Novo Nordisk Revenue 2025: $48.18B
In 2025, Novo Nordisk reported revenue of 309.06B DKK ($48.18B), grew 6.4% from 2024. This figure represents the highest annual value in the available history.
Novo Nordisk Revenue 2024: $41.53B
Novo Nordisk revenue in 2024 was 290.40B DKK ($41.53B), grew 25.0% from 2023.
Novo Nordisk Revenue 2023: $33.52B
2023's revenue for Novo Nordisk came in at 232.26B DKK ($33.52B), surged 31.3% from 2022.
Novo Nordisk Revenue 2022: $24.31B
Novo Nordisk posted revenue of 176.95B DKK ($24.31B) in 2022, grew 25.7% from 2021.
Novo Nordisk Revenue 2021: $21.65B
Novo Nordisk revenue in 2021 was 140.80B DKK ($21.65B).
See more financial history for Novo Nordisk (NVO).
Sector peers by Revenue
Healthcare peers of Novo Nordisk (NVO), ranked by their latest revenue
| $447.57B | |
| $94.19B | |
| $65.18B | |
| $64.93B | |
| $61.16B | |
| $58.74B | |
| $44.56B | |
| $36.74B |
- $447.57B
- $94.19B
- $65.18B
- $64.93B
- $61.16B
- $58.74B
- $36.74B
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation